DUBLIN, May 10, 2021 /PRNewswire/ -- Medtronic plc
(NYSE:MDT), the global leader in medical technology, today
announced the U.S. commercial launch of the SonarMed™ airway
monitoring system. The first and only device of its kind, the
SonarMed airway monitoring system utilizes acoustic technology to
check for endotracheal tube (ETT) obstruction and verify position
in real-time, giving clinicians vital information required to make
more informed, life-saving decisions for their smallest
Globally, 415,000 neonates and infants require invasive
mechanical ventilation per year and are intubated for greater than
24 hours. Despite recommendations and reduction efforts, 75,000, or
about one in five, of these neonates and infants will experience at
least one unplanned extubation (UE). In the NICU, UEs are a
significant safety concern for neonates and newborns and are the
most common adverse event during mechanical
ventilation.1 These events can lead to increased length
of stay and hospital costs.2 Adoption of the SonarMed
airway monitoring system can help reduce the frequency of these
events, which in turn can help improve outcomes and reduce
"The SonarMed airway monitoring device has revolutionized the
way we care for our littlest patients. There is no other device in
the world that can tell you where the endotracheal tube is located
within the airway continuously in real-time, and whether the tube
is obstructed or even partially occluded," said Jamie W. Powers, M.D., MBA, neonatologist at
Huntington Hospital in Pasadena,
California. "At our hospital, this information has led to a
drastic reduction in the number of x-rays performed and marked
improvement in the effective suctioning of the airway. It also
provides the care team and parents the added reassurance that the
breathing tube is where it needs to be while repositioning the
patient and during kangaroo care. In our institution it has become
the new standard of care for all intubated infants."
The SonarMed airway monitoring system is the first and only
FDA-cleared airway monitoring system that provides timely
notifications and specific measurements that help enable a
coordinated response to address potentially critical events such as
ETT movement and migration.
"Clinicians face unique challenges in the neonatal intensive
care unit (NICU) and pediatric intensive care unit (PICU) daily,
ranging from managing oxygenation within extremely tight ranges, to
keeping family members informed and comforted. With our innovative
technology, this fragile patient group is continuously monitored
with a real-time and accurate device that may help improve a
clinician's ability to manage the airway and enhance outcomes for
our smallest, most vulnerable critical care patients," said
Ariel MacTavish, president of the
Respiratory Interventions business, which is part of the Medical
Surgical Portfolio at Medtronic. "Our goal with introducing the
SonarMed technology is to help solve a clinical need to reduce the
number of unplanned extubations to help these vulnerable patients
start their lives in the healthiest way."
SonarMed, which was acquired by Medtronic in December
2020, specializes in developing solutions that increase
patient safety while significantly decreasing healthcare costs.
"With Medtronic's extensive market presence, clinical
leadership, and market development expertise, coupled with
SonarMed's innovative technology, we are confident that together,
we can potentially help save the lives of thousands of infants,"
said Tom Bumgardner, strategic
planning program director, Medtronic Respiratory Interventions, and
former SonarMed CEO.
For additional information about the SonarMed airway monitoring
system, please visit: medtronic.com/sonarmed.
About SonarMed™ Airway Monitoring System
airway monitoring system includes a bedside monitor and single-use
sensor. The SonarMed sensor fits any brand of standard endotracheal
tube (ETT) in sizes ranging from neonatal to pediatric populations
(2.5 mm–6.0mm ID) and attaches noninvasively to the proximal end of
the ETT by replacing the 15-mm connector within the ventilator
circuit. The SonarMed monitor incorporates an easy-to-read color
screen that can display any change in ETT status.
Medtronic plc (www.medtronic.com),
headquartered in Dublin, Ireland,
is among the world's largest medical technology, services, and
solutions companies – alleviating pain, restoring health, and
extending life for millions of people around the world. Medtronic
employs more than 90,000 people worldwide, serving physicians,
hospitals, and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
The SonarMed Airway Monitoring System should not be used as
the sole basis for diagnosis or therapy and is intended only as an
adjunct in patient assessment.
1 The Adverse Impact of Unplanned Extubation in
a Cohort of Critically Ill Neonates. 2019. KK Kambestad, A Huack, S
Nair, R Chapman, S Chin, L Langga, E Mounger, E Guerrero, NP Iyer. 10.4187/respcare.06721.
2 Roddy DJ, Spaeder MC, Pastor W, Stockwell DC,
Klugman D. Unplanned Extubations in Children: Impact on Hospital
Cost and Length of Stay. Pediatr Crit Care Med .
View original content to download
SOURCE Medtronic plc